- Recent data on ProMetic’s orally active drug candidates demonstrates efficacy in diabetic kidney disease and other fibrotic models
LAVAL, QUEBEC, CANADA – November 1, 2012 – ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic” or the “Corporation”) is presenting today new and positive data on two of its orally active anti-fibrotic drug candidates at the annual Meeting of the American Society of Nephrology in San Diego, California.
Diabetic nephropathy is increasing in incidence and is now the number one cause of end-stage renal disease. In a gold standard animal model used to mimic the long term detrimental effects of diabetes on the kidney and the liver, ProMetic’s once a day oral treatment with PBI-4050 demonstrated a significant reduction in kidney hyperfiltration, proteinuria and hepatic steatosis. These results suggest that PBI-4050 could be potentially be used as a novel therapy for diabetic kidney disease and liver steatosis. PBI-4050 has been shown to treat fibrosis in several different animal models and is now being prepared to enter into clinical development in 2013.
Other interesting data being presented at the ASN confirms the effect of ProMetic’s drug candidates on interstitial fibroblasts which are the principal cause of organ fibrosis.
“TGF-β-stimulated fibroblasts secrete connective tissue growth factor (CTGF) which functions as a downstream mediator of TGF-β action on fibroblastic cell types are important in collagen production. ProMetic’s drug candidates have demonstrated the inhibition of CTGF and collagen production in murine and human fibroblasts and consequently to reduce kidney fibrosis in 5/6-nephrectomized rats and unilateral ureteral obstruction models”, said Dr. Lyne Gagnon, ProMetic’s Director of Research and Developement, Biology.
Thursday, November 1, 2012, 10:00 AM – 12:00 PM (PST) Poster Session Diabetes: Basic – Cell Biology, Models -1, # TH-PO482
3175 “Oral Treatment with a Novel First-in-Class Anti-Fibrotic Compound PBI-4050 Reduces Kidney Hyperfiltration, Proteinuria and Hepatic Steatosis in the Diabetic db/db Mouse Model”
Thursday, November 1, 2012, 10:00 AM – 12:00 PM (PST) Poster Session Pathobiology:
Basic/Experimental Pathology – I # TH-PO969
3170 “PBI-4419, a Novel First-in-Class Anti-Fibrotic Compound, Inhibits CTGF and Collagen Production in Murine and Human Fibroblasts and Reduces Kidney Fibrosis in 5/6-Nephrectomized and Unilateral Ureteral Obstruction Rat Models”
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://prometic.com/) is a global biopharmaceutical company specializing in the design of small molecules that mimic unique and specific interactions between proteins, research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM technology. This technology is used in large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. ProMetic is also active in developing its own novel therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic’s Annual Information Form for the year ended December 31, 2011, under the heading “Risk and Uncertainties related to ProMetic’s business”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.